{"entity":{"id":"nct06383078","kind":"trial","name":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of liposomal irinotecan, cAPOX (capecitabine, oxaliplatin), tegafur, gimeracil and oteracil (S-1), leucovorin (folinic acid) and other drugs in pancreatic cancer, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.","summary":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer is a phase 2, randomised interventional study registered as NCT06383078 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 120 participants, started 2024-04-20 and due to reach its primary completion in 2027-03-01. Interventions recorded: HR070803; Oxaliplatin; Tegafur; Folinic acid; 5-Fluorouracil. Conditions listed: Efficacy and Safety. Primary outcome: 1-year Disease-free survival rate. Pancreatic eligibility wording from the registry: \"Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06383078","url":"https://clinicaltrials.gov/study/NCT06383078"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["liposomal-irinotecan","capox","tegafur-gimeracil-oteracil","leucovorin","fluorouracil"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06383078","phase":"2","setting":"HR070803 in Combination With Oxaliplatin Plus Tegafur Versus HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate as Adjuvant Therapy for Pancreatic Cancer: A Multicenter, Multi-cohort, Randomized, Phase II Study","sponsor":"The First Affiliated Hospital with Nanjing Medical University","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06383078/","neighbours":{"cancer":[{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/"},{"id":"tegafur-gimeracil-oteracil","kind":"drug","name":"Tegafur, gimeracil and oteracil (S-1)","route":"/drugs/tegafur-gimeracil-oteracil/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}